Skip to content
Menu

HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $250

Benzinga Newsdesk 2 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $455 to $250.

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $455 to $250.

Read at benzinga.com